Xeris Biopharma Holdings, Inc./$XERS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Ticker

$XERS
Primary listing

Industry

Pharmaceuticals

Employees

394

XERS Metrics

BasicAdvanced
$804M
-
-$0.30
0.91
-

Bulls say / Bears say

Xeris Biopharma reported a 48% year-over-year increase in total revenue for Q1 2025, reaching over $60 million, with Recorlev® revenue growing 141% year-over-year. (Xeris Biopharma Press Release)
The company announced the approval of a supplemental New Drug Application for Gvoke VialDx™, a ready-to-dilute liquid glucagon, expected to be available in Q3 2025. (Xeris Biopharma Press Release)
Analyst firms have raised their price targets for Xeris Biopharma, with Craig Hallum increasing its target from $5.00 to $6.50 and maintaining a 'buy' rating. (MarketBeat)
Insider selling activity was noted, with insider Beth Hecht selling 40,000 shares in March 2025, potentially signaling concerns about future performance. (MarketBeat)
Keveyis® revenue declined by 23% to $12.2 million in Q3 2024, indicating potential challenges in that product segment. (StockTitan)
Piper Sandler downgraded Xeris Biopharma from an 'overweight' to a 'neutral' rating, setting a $3.00 price objective, reflecting cautious sentiment. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $XERS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs